Cargando…

Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines

COVID-19 is marked by extensive damage to the respiratory system, often accompanied by systemic manifestations, due to both viral cytopathic effects and hyperinflammatory syndrome. Therefore, the development of new therapeutic strategies or drug repurposing aiming to control virus replication and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bezerra, Bruno Braz, Silva, Gustavo Peixoto Duarte da, Coelho, Sharton Vinicius Antunes, Correa, Isadora Alonso, Souza, Marcos Romario Matos de, Macedo, Keylla Vitória Gomes, Matos, Bruna Machado, Tanuri, Amilcar, Matassoli, Flavio Lemos, Costa, Luciana Jesus da, Hildreth, James E.K., Arruda, Luciana Barros de
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250893/
https://www.ncbi.nlm.nih.gov/pubmed/35798224
http://dx.doi.org/10.1016/j.antiviral.2022.105373
_version_ 1784739908028465152
author Bezerra, Bruno Braz
Silva, Gustavo Peixoto Duarte da
Coelho, Sharton Vinicius Antunes
Correa, Isadora Alonso
Souza, Marcos Romario Matos de
Macedo, Keylla Vitória Gomes
Matos, Bruna Machado
Tanuri, Amilcar
Matassoli, Flavio Lemos
Costa, Luciana Jesus da
Hildreth, James E.K.
Arruda, Luciana Barros de
author_facet Bezerra, Bruno Braz
Silva, Gustavo Peixoto Duarte da
Coelho, Sharton Vinicius Antunes
Correa, Isadora Alonso
Souza, Marcos Romario Matos de
Macedo, Keylla Vitória Gomes
Matos, Bruna Machado
Tanuri, Amilcar
Matassoli, Flavio Lemos
Costa, Luciana Jesus da
Hildreth, James E.K.
Arruda, Luciana Barros de
author_sort Bezerra, Bruno Braz
collection PubMed
description COVID-19 is marked by extensive damage to the respiratory system, often accompanied by systemic manifestations, due to both viral cytopathic effects and hyperinflammatory syndrome. Therefore, the development of new therapeutic strategies or drug repurposing aiming to control virus replication and inflammation are required to mitigate the impact of the disease. Hydroxypropyl-beta-cyclodextrin (HP-BCD) is a cholesterol-sequestering agent with antiviral activity that has been demonstrated against enveloped viruses in in vitro and in vivo experimental models. We also demonstrated that HP-BCD has an immunomodulatory effect, inhibiting the production of selected proinflammatory cytokines induced by microbial products. Importantly, this drug has been used in humans for decades as an excipient in drug delivery systems and as a therapeutic agent in the treatment of Niemann pick C disease. The safety profile for this compound is well established. Here, we investigated whether HP-BCD would affect SARS-CoV-2 replication and virus-induced inflammatory response, using established cell lines and primary human cells. Treating virus or cells with HP-BCD significantly inhibited SARS-CoV-2 replication with a high selective index. A broad activity against distinct SARS-CoV-2 variants was evidenced by a remarkable reduction in the release of infectious particles. The drug did not alter ACE2 surface expression, but affected cholesterol accumulation into intracellular replication complexes, lowering virus RNA and protein levels, and reducing virus-induced cytopathic effects. Virus replication was also impaired by HP-BCD in Calu-3 pulmonary cell line and human primary monocytes, in which not only the virus, but also the production of proinflammatory cytokines were significantly inhibited. Given the pathophysiology of COVID-19 disease, these data indicate that the use HP-BCD, which inhibits both SARS-CoV2 replication and production of proinflammatory cytokines, as a potential COVID-19 therapeutic warrants further investigation.
format Online
Article
Text
id pubmed-9250893
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-92508932022-07-05 Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines Bezerra, Bruno Braz Silva, Gustavo Peixoto Duarte da Coelho, Sharton Vinicius Antunes Correa, Isadora Alonso Souza, Marcos Romario Matos de Macedo, Keylla Vitória Gomes Matos, Bruna Machado Tanuri, Amilcar Matassoli, Flavio Lemos Costa, Luciana Jesus da Hildreth, James E.K. Arruda, Luciana Barros de Antiviral Res Article COVID-19 is marked by extensive damage to the respiratory system, often accompanied by systemic manifestations, due to both viral cytopathic effects and hyperinflammatory syndrome. Therefore, the development of new therapeutic strategies or drug repurposing aiming to control virus replication and inflammation are required to mitigate the impact of the disease. Hydroxypropyl-beta-cyclodextrin (HP-BCD) is a cholesterol-sequestering agent with antiviral activity that has been demonstrated against enveloped viruses in in vitro and in vivo experimental models. We also demonstrated that HP-BCD has an immunomodulatory effect, inhibiting the production of selected proinflammatory cytokines induced by microbial products. Importantly, this drug has been used in humans for decades as an excipient in drug delivery systems and as a therapeutic agent in the treatment of Niemann pick C disease. The safety profile for this compound is well established. Here, we investigated whether HP-BCD would affect SARS-CoV-2 replication and virus-induced inflammatory response, using established cell lines and primary human cells. Treating virus or cells with HP-BCD significantly inhibited SARS-CoV-2 replication with a high selective index. A broad activity against distinct SARS-CoV-2 variants was evidenced by a remarkable reduction in the release of infectious particles. The drug did not alter ACE2 surface expression, but affected cholesterol accumulation into intracellular replication complexes, lowering virus RNA and protein levels, and reducing virus-induced cytopathic effects. Virus replication was also impaired by HP-BCD in Calu-3 pulmonary cell line and human primary monocytes, in which not only the virus, but also the production of proinflammatory cytokines were significantly inhibited. Given the pathophysiology of COVID-19 disease, these data indicate that the use HP-BCD, which inhibits both SARS-CoV2 replication and production of proinflammatory cytokines, as a potential COVID-19 therapeutic warrants further investigation. The Authors. Published by Elsevier B.V. 2022-09 2022-07-04 /pmc/articles/PMC9250893/ /pubmed/35798224 http://dx.doi.org/10.1016/j.antiviral.2022.105373 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bezerra, Bruno Braz
Silva, Gustavo Peixoto Duarte da
Coelho, Sharton Vinicius Antunes
Correa, Isadora Alonso
Souza, Marcos Romario Matos de
Macedo, Keylla Vitória Gomes
Matos, Bruna Machado
Tanuri, Amilcar
Matassoli, Flavio Lemos
Costa, Luciana Jesus da
Hildreth, James E.K.
Arruda, Luciana Barros de
Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines
title Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines
title_full Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines
title_fullStr Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines
title_full_unstemmed Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines
title_short Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines
title_sort hydroxypropyl-beta-cyclodextrin (hp-bcd) inhibits sars-cov-2 replication and virus-induced inflammatory cytokines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250893/
https://www.ncbi.nlm.nih.gov/pubmed/35798224
http://dx.doi.org/10.1016/j.antiviral.2022.105373
work_keys_str_mv AT bezerrabrunobraz hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT silvagustavopeixotoduarteda hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT coelhoshartonviniciusantunes hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT correaisadoraalonso hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT souzamarcosromariomatosde hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT macedokeyllavitoriagomes hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT matosbrunamachado hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT tanuriamilcar hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT matassoliflaviolemos hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT costalucianajesusda hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT hildrethjamesek hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines
AT arrudalucianabarrosde hydroxypropylbetacyclodextrinhpbcdinhibitssarscov2replicationandvirusinducedinflammatorycytokines